Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...

NEW YORK, N.Y. – Pfizer Inc. on Monday released detailed analyses of myocarditis cases linked to its COVID-19 vaccine, ...

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

Shares of Moderna and BioNTech fell on Monday, likely in response to a FDA official's memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children. Concern about that ...

May Parsons became the first person in the world to deliver the COVID-19 vaccine outside of a clinical trial at University ...

The FDA’s top vaccine regulator asserted in a staff email that the Covid vaccine caused at least 10 kids' deaths, but experts ...

Elders need to get shots this season to be protected against major viruses and other illnesses. There are many to choose from ...

French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. | French vaccine maker Valneva is closing down a site that houses both ...